Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade

被引:0
|
作者
Oh, Kyu-Young [1 ,2 ,3 ]
Hong, Seong-Doo [2 ,3 ,4 ,5 ]
Yoon, Hye-Jung [2 ,3 ,4 ,5 ]
机构
[1] Dankook Univ, Coll Dent, Dept Oral Pathol, Cheonan, South Korea
[2] Seoul Natl Univ, Sch Dent, Dept Oral Pathol, Seoul, South Korea
[3] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea
[4] Seoul Natl Univ, Sch Dent, Dept Oral Pathol, 101 Daehak Ro, Seoul, South Korea
[5] Seoul Natl Univ, Dent Res Inst, 101 Daehak Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
immune checkpoint blockade; odontogenic carcinoma; PD-L1; tumor immune microenvironment; INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; EXPRESSION; CANCER; PD-L1; CELLS;
D O I
10.1111/jop.13525
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Despite recent advances in the use of immune checkpoint blockade (ICB) across various cancer types, its efficacy in odontogenic carcinomas remains unexplored. This study aims to investigate PD-L1 expression and the tumor immune microenvironment (TIME) in odontogenic carcinomas to determine the therapeutic potential of ICB and the significance of immune markers. Methods: The expressions of PD-L1 and T cell markers (CD3, CD8, and FOXP3) were visualized by immunohistochemistry in 21 tissue samples of odontogenic carcinomas. Tumoral PD-L1 expression and the density and spatial distribution of T cell subsets were evaluated, from which TIME was determined. The associations of the variables with clinicopathological and prognostic factors were statistically analyzed. Results: PD-L1 was positively expressed in 52.4% (11/21) of the cases studied. Among tumor types, ameloblastic carcinoma showed significantly higher PD-L1 expression (p = 0.016). TIME based on the intratumoral and stromal T cell distribution was immune-inflamed in 61.9% (13/21) and immune-excluded in 38.1% (8/21), with no immune-desert cases. PD-L1 expression was associated with the densities of all intratumoral T cell subsets (p = 0.03 for CD3, p = 0.03 for CD8, and p = 0.008 for FOXP3) but not with those of stromal T cells. High PD-L1 expression was associated with larger tumor size (p = 0.021), while the intratumoral CD8/CD3 ratio was inversely correlated with tumor size (p = 0.048). Conclusion: These findings indicate the involvement of adaptive immune resistance in a subset of odontogenic carcinomas and support the therapeutic potential of ICB in patients with these rare malignancies.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 50 条
  • [1] Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
    Genova, Carlo
    Dellepiane, Chiara
    Carrega, Paolo
    Sommariva, Sara
    Ferlazzo, Guido
    Pronzato, Paolo
    Gangemi, Rosaria
    Filaci, Gilberto
    Coco, Simona
    Croce, Michela
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [2] The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Petitprez, Florent
    Meylan, Maxime
    de Reynies, Aurelien
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [3] Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy
    Menzel, Johannes
    Black, Joshua C.
    [J]. CANCER DISCOVERY, 2020, 10 (02) : 179 - 181
  • [4] The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Russell, Bonnie L.
    Sooklal, Selisha A.
    Malindisa, Sibusiso T.
    Daka, Lembelani Jonathan
    Ntwasa, Monde
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Antibody mediated blockade of phosphatidylserine improves immune checkpoint blockade by repolarizing immune suppressive mechanisms of the tumor microenvironment
    Hutchins, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Li, Yaqi
    Liu, Jing
    Gao, Long
    Liu, Yuan
    Meng, Fang
    Li, Xiaoan
    Qin, F. Xiao-Feng
    [J]. IMMUNOLOGY LETTERS, 2020, 220 : 88 - 96
  • [7] Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies
    Devereaux, Kelly A.
    Charu, Vivek
    Zhao, Shuchun
    Charville, Gregory W.
    Bangs, Charles D.
    van de Rijn, Matt
    Cherry, Athena M.
    Natkunam, Yasodha
    [J]. HUMAN PATHOLOGY, 2018, 82 : 39 - 45
  • [8] Antibody mediated blockade of phosphatidylserine to enhance immune checkpoint blockade by repolarizing immune suppressive mechanisms of the tumor microenvironment.
    Hutchins, Jeff
    Gray, Michael J.
    Huang, Xianming
    Gong, Jian
    Hatch, Michaela M. S.
    Van Nguyen
    Hughes, Christopher C. W.
    Brekken, Rolf A.
    Freimark, Bruce D.
    Gerber, David E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
    Ruiwen Ruan
    Li Li
    Xuan Li
    Chunye Huang
    Zhanmin Zhang
    Hongguang Zhong
    Shaocheng Zeng
    Qianqian Shi
    Yang Xia
    Qinru Zeng
    Qin Wen
    Jingyi Chen
    Xiaofeng Dai
    Jianping Xiong
    Xiaojun Xiang
    Wan Lei
    Jun Deng
    [J]. Molecular Cancer, 22
  • [10] Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
    Ruan, Ruiwen
    Li, Li
    Li, Xuan
    Huang, Chunye
    Zhang, Zhanmin
    Zhong, Hongguang
    Zeng, Shaocheng
    Shi, Qianqian
    Xia, Yang
    Zeng, Qinru
    Wen, Qin
    Chen, Jingyi
    Dai, Xiaofeng
    Xiong, Jianping
    Xiang, Xiaojun
    Lei, Wan
    Deng, Jun
    [J]. MOLECULAR CANCER, 2023, 22 (01)